SomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumors
12 Setembro 2023 - 10:00AM
In a
new paper published in Nature's Scientific
Reports, researchers at SomaLogic Inc. studied the value
of protein biomarkers in the early detection of cancer and the
stratification of cancerous tumors. The research team identified 15
blood proteins shared among all cancer types as well as models to
stratify tumor types. The goal of this research was to identify
protein biomarkers that could be used to detect early-stage cancer
during regular screenings, which could increase treatment options
for patients, minimize the likelihood of chemotherapy resistance
and reduce the risk of tumor metastases.
Early detection of cancer offers the best chance of successful
treatment, but many cancers are only diagnosed at an advanced stage
after patients exhibit symptoms or the disease is found during an
unrelated procedure. Currently, screening tests for breast, colon,
cervical, prostate and lung cancer are limited by their lack of
sensitivity, invasiveness, high false positives and low patient
compliance. Using the SomaScan® platform and machine learning,
researchers at SomaLogic sought to overcome these challenges and
limitations by exploring the possibility of identifying
tumor-associated proteins in a mouse model that can be detected
with a simple blood test early in the disease process and use them
to establish the presence and identity of cancerous tumors.
“In addition to tumor-specific biomarker models, we were also
able to identify sentinel proteins in plasma for four different
tumor types,” said SomaLogic Chief Science Officer Nebojsa Janjic,
who was an author on the paper. “Using our proteomics technology,
we also developed a pan-cancer prediction model that can detect the
presence of ovarian, colon and breast cancer tumors as small as
0.15 inches (<0.75mm3) by measuring circulating proteins in a
small blood sample.”
Since lung cancer is the leading cause of mortality from cancer,
the team focused on two human non-small cell lung cancer cell
lines. They then expanded their research to include breast, colon,
and ovarian cancer cell lines. Protein patterns allowed the
researchers to identify biomarkers unique for each tumor type, as
well as shared biomarkers that can detect the presence and predict
the volume of these tumors.
For more than twenty years, SomaLogic has grown from its roots
in the research lab to become a global leader in proteomics with
technology that delivers the quality and quantity of biological
insights life science researchers need - from lab to last mile.
About SomaLogic SomaLogic is catalyzing
drug research and development and biomarker identification as a
global leader in proteomics technology. With a single 55 microliter
plasma or serum sample, SomaLogic can run 7,000 protein
measurements, covering more than a third of the approximately
20,000 proteins in the human body. For more than 20 years we’ve
supported pharmaceutical companies, and academic and contract
research organizations who rely on our protein detection and
analysis technologies to fuel drug, disease, and treatment
discoveries in such areas as oncology, diabetes, and
cardiovascular, liver and metabolic diseases. Find out more at
www.somalogic.com and follow @somalogic on LinkedIn.
Forward Looking Statements This press
release contains certain forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
All statements, other than statements of historical fact included
in this press release, regarding our strategy, future operations,
financial position, estimated revenues, projections, prospects,
plans and objectives of management are forward-looking statements.
These forward-looking statements generally are identified by the
words “believe,” “project,” “forecast,” “guidance,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“continue,” “will likely result,” “possible,” “potential,”
“predict,” “pursue,” “target” and similar expressions, although not
all forward-looking statements contain such identifying words.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements do not guarantee
future performance and involve known and unknown risks,
uncertainties and other factors. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including factors which are
beyond SomaLogic’s control. You should carefully consider these
risks and uncertainties, including, but not limited to, those
factors described under Part I, Item 1A – “Risk Factors” in our
Annual Report on Form 10-K and other filings we make with the
Securities and Exchange Commission. These filings identify and
address important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and SomaLogic assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Should one or more of these risks or
uncertainties materialize, or should any of the assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. The Company will not
and does not undertake any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
SomaLogic Media Contact Emilia Costales
720-798-5054 ecostales@somalogic.com
SomaLogic Investor ContactMarissa BychGilmartin
Group LLCinvestors@somalogic.com
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024